Treatment to improve bone marrow function after transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new treatment to help your bone marrow make healthy blood cells after a transplant or if aplastic anemia has come back. It aims to improve blood counts and reduce the need for blood transfusions or growth factor injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have poor graft function after a bone marrow transplant, or your aplastic anemia has come back or not responded to treatment.
- You need to be in generally good health (able to do daily activities without much help).
- Your doctor expects you to live at least 6 more months.
- You cannot have severe graft-versus-host disease (where donor cells attack your body).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
Hear when a new Poor Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.